CorMedix Inc. is a U.S. specialty biopharmaceutical company that has converted a single-asset DefenCath launch into a diversified hospital infectious disease franchise in roughly twelve months. The August 2025 Melinta acquisition layered a seven-product portfolio onto the original catheter lock solution business, and the integrated platform now spans anti-infectives, a catheter lock, and a cardiovascular product. The result is a specialty pharma issuer whose revenue base has effectively tripled in the trailing year.
The equity story for the back half of 2026 and into 2027 sits on three operational pillars. The first is the post-TDAPA reimbursement reset that began on July 1, 2026, and is expected to compress DefenCath net pricing in the second half. The second is the REZZAYO label expansion that turned positive on April 27 of this year with the ReSPECT Phase III readout. The label expansion carries a 2027 commercialization target. The third is the integration of a hospital-focused sales footprint that supports cross-selling across the catheter lock, anti-infective, and cardiovascular product lines. Each pillar carries a distinct catalyst window that the equity can price independently or in combination through the next six quarters.
The investment proposition, in equity research terms, is a profitable specialty pharma platform with a single dominant product now exposed to a Medicare reimbursement reset, a pipeline catalyst in antifungal prophylaxis, and a manageable debt stack. The market has assigned an equity capitalization near $660M to the franchise at an $8.47 reference price. The equity trades below the midpoint of a fifty-two week range that runs from $6.13 to $13.83, reflecting a balanced setup between cash flow visibility and reimbursement uncertainty. The combination of a 39% cash-to-market-cap ratio and a 4% convertible coupon above the current share price is the right way to frame the floor under the equity. The remaining $57.5M of buyback authorization reinforces that floor through the post-TDAPA reset window. The post-TDAPA pricing reset, the REZZAYO label expansion, and the broader multi-product integration together determine whether the equity resolves toward the upper or lower end of the current range over the next four to six quarters.